Nirsevimab

Where the papers sit

22 papers from the last 6 months study nirsevimab directly · updated from PubMed 10 Oct 2026

• Infant RSV Prevention

  Infant RSV prevention is being compared across nirsevimab, maternal RSVpreF vaccination, and combined strategies. Real-world studies focus on protection duration and reductions in RSV-related hospitalization among high-risk infants. Economic analyses increasingly weigh population-wide immunization against targeted use. Breakthrough RSV-B infections raise a continuing concern about nirsevimab resistance.

  8 papers · 36.4%

• RSV Immunization Programs

  RSV immunization programs are being judged by coverage, uptake, safety, and cost-effectiveness. Nirsevimab and maternal RSVpreF vaccination are modelled as separate or hybrid approaches for preventing infant disease. Implementation studies identify newborn uptake and pediatrician knowledge as practical constraints. Post-licensure surveillance is expanding safety assessment to children aged 0–24 months.

  6 papers · 27.3%

• RSV Immunization Acceptance

  RSV immunization decisions center on acceptance, product choice, timing, and post-licensure safety. Surveys examine pregnant women’s preferences for maternal vaccination, postpartum acceptance of nirsevimab, and pediatricians’ knowledge of available products. Policy modelling compares seasonal with year-round infant immunization to reduce hospitalizations. Early program reports and Canadian surveillance are adding practical uptake and safety evidence.

  6 papers · 27.3%

• RSV Prevention Outcomes

  RSV prevention is being measured through outcomes beyond infection alone, especially hospitalization and acute otitis media. Interrupted time-series data associate nirsevimab with fewer acute otitis media infections in infants. Multicentre studies report reductions in pediatric RSV hospitalizations after regional immunization, but the size of benefit varies between settings. Heterogeneous effects remain an important question for program evaluation.

  2 papers · 9.1%